The overall strengths and weaknesses of Capmatinib and its journey from a preclinical profile to potential FDA approval. The evidence provided is limited to research conducted by NPC and potential future success of Capmatinib profits. Therefore
an open-mind should be maintained when interpreting NPC validity of laboratory experiment and clinical trials.